Roundview Capital LLC lowered its position in Celcuity, Inc. (NASDAQ:CELC – Free Report) by 59.5% in the 4th quarter, according to the company in its most recent filing with the SEC. The fund owned 2,778 shares of the company’s stock after selling 4,079 shares during the quarter. Roundview Capital LLC’s holdings in Celcuity were worth $277,000 as of its most recent SEC filing.
Several other large investors also recently added to or reduced their stakes in CELC. Apis Capital Advisors LLC purchased a new stake in Celcuity in the 3rd quarter worth about $38,334,000. UBS Group AG lifted its position in shares of Celcuity by 910.1% during the third quarter. UBS Group AG now owns 854,483 shares of the company’s stock worth $42,211,000 after acquiring an additional 769,891 shares in the last quarter. Deerfield Management Company L.P. purchased a new stake in shares of Celcuity during the third quarter worth $36,236,000. Alliancebernstein L.P. boosted its holdings in shares of Celcuity by 2,208.6% in the third quarter. Alliancebernstein L.P. now owns 652,649 shares of the company’s stock worth $32,241,000 after acquiring an additional 624,379 shares during the period. Finally, Soleus Capital Management L.P. boosted its holdings in shares of Celcuity by 17.0% in the second quarter. Soleus Capital Management L.P. now owns 3,011,818 shares of the company’s stock worth $40,208,000 after acquiring an additional 437,696 shares during the period. Hedge funds and other institutional investors own 63.33% of the company’s stock.
Wall Street Analysts Forecast Growth
A number of analysts recently issued reports on CELC shares. Needham & Company LLC reiterated a “buy” rating and set a $157.00 price objective on shares of Celcuity in a research note on Friday, May 15th. Guggenheim increased their price objective on Celcuity from $135.00 to $165.00 and gave the stock a “buy” rating in a report on Monday, May 4th. Citizens Jmp increased their price objective on Celcuity from $150.00 to $160.00 and gave the stock a “market outperform” rating in a report on Monday, May 4th. Weiss Ratings cut Celcuity from a “sell (d-)” rating to a “sell (e+)” rating in a report on Tuesday, May 19th. Finally, Wells Fargo & Company increased their price objective on Celcuity from $150.00 to $183.00 and gave the stock an “overweight” rating in a report on Friday, May 15th. Eleven research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average price target of $150.27.
Insider Buying and Selling at Celcuity
In related news, Director David Dalvey sold 25,000 shares of Celcuity stock in a transaction on Monday, May 4th. The stock was sold at an average price of $140.68, for a total transaction of $3,517,000.00. Following the completion of the sale, the director owned 65,000 shares of the company’s stock, valued at approximately $9,144,200. This trade represents a 27.78% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Richard E. Buller sold 9,000 shares of Celcuity stock in a transaction on Monday, May 4th. The shares were sold at an average price of $140.46, for a total value of $1,264,140.00. Following the sale, the director directly owned 6,760 shares of the company’s stock, valued at $949,509.60. This represents a 57.11% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 37,000 shares of company stock valued at $5,111,950 in the last three months. 13.33% of the stock is owned by corporate insiders.
Celcuity Price Performance
NASDAQ:CELC opened at $130.91 on Friday. The firm has a market capitalization of $6.38 billion, a price-to-earnings ratio of -33.57 and a beta of 0.09. Celcuity, Inc. has a 52-week low of $10.50 and a 52-week high of $151.02. The stock has a fifty day moving average of $122.68 and a 200 day moving average of $110.78. The company has a debt-to-equity ratio of 6.04, a quick ratio of 12.31 and a current ratio of 12.31.
Celcuity (NASDAQ:CELC – Get Free Report) last posted its quarterly earnings data on Thursday, May 14th. The company reported ($0.97) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.07) by $0.10. On average, research analysts expect that Celcuity, Inc. will post -3.96 EPS for the current fiscal year.
About Celcuity
Celcuity, Inc is a clinical-stage biotechnology company specializing in precision oncology diagnostics. The company develops and commercializes predictive biomarker assays designed to identify which patients are most likely to benefit from targeted cancer therapies. By integrating functional profiling of tumor cells with molecular analyses, Celcuity seeks to optimize treatment selection and improve outcomes for patients with solid tumors.
Celcuity’s proprietary platform evaluates tumor cell sensitivity to various therapeutic agents using ex vivo assays that measure DNA damage response and other critical pathways.
Read More
- Five stocks we like better than Celcuity
- 3 Stocks Rallying on Micron’s Price Boost: Substance or Hype?
- Snowflake and the Snowballing Impact of its AI Flywheel
- AI’s Biggest Bottleneck Could Make These 2 Stocks Soar
- These 3 Beaten-Down Stocks Just Saw $25 Million in Insider Buying
Want to see what other hedge funds are holding CELC? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Celcuity, Inc. (NASDAQ:CELC – Free Report).
Receive News & Ratings for Celcuity Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celcuity and related companies with MarketBeat.com's FREE daily email newsletter.
